Log in

Relevant bibliographies by topics / Mutation database / Journal articles

Journal articles on the topic 'Mutation database'

To see the other types of publications on this topic, follow the link: Mutation database.

Author: Grafiati

Published: 9 March 2023

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mutation database.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gottlieb, Bruce, Lenore K. Beitel, and Mark A. Trifiro. "Variable expressivity and mutation databases: The androgen receptor gene mutations database." Human Mutation 17, no. 5 (2001): 382–88. http://dx.doi.org/10.1002/humu.1113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lee, Joon-Hyop, Jiyoung Ahn, Won Seo Park, Eun Kyung Choe, Eunyoung Kim, Rumi Shin, Seung Chul Heo, et al. "Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study." Journal of Clinical Medicine 8, no. 1 (January 17, 2019): 111. http://dx.doi.org/10.3390/jcm8010111.

Full text

Abstract:

Background: We investigated the associations between v-Raf murine sarcoma viral oncogene homolog B1 (BRAFV600E, henceforth BRAF) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and colorectal cancer (CRC) prognosis, using The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GSE39582) datasets. Materials and Methods: The effects of BRAF and KRAS mutations on overall survival (OS) and disease-free survival (DFS) of CRC were evaluated. Results: The mutational status of BRAF and KRAS genes was not associated with overall survival (OS) or DFS of the CRC patients drawn from the TCGA database. The 3-year OS and DFS rates of the BRAF mutation (+) vs. mutation (−) groups were 92.6% vs. 90.4% and 79.7% vs. 68.4%, respectively. The 3-year OS and DFS rates of the KRAS mutation (+) vs. mutation (−) groups were 90.4% vs. 90.5% and 65.3% vs. 73.5%, respectively. In stage II patients, however, the 3-year OS rate was lower in the BRAF mutation (+) group than in the mutation (−) group (85.5% vs. 97.7%, p <0.001). The mutational status of BRAF genes of 497 CRC patients drawn from the GSE39582 database was not associated with OS or DFS. The 3-year OS and DFS rates of BRAF mutation (+) vs. mutation (−) groups were 75.7% vs. 78.9% and 73.6% vs. 71.1%, respectively. However, KRAS mutational status had an effect on 3-year OS rate (71.9% mutation (+) vs. 83% mutation (−), p = 0.05) and DFS rate (66.3% mutation (+) vs. 74.6% mutation (−), p = 0.013). Conclusions: We found no consistent association between the mutational status of BRAF nor KRAS and the OS and DFS of CRC patients from the TCGA and GSE39582 databases. Studies with longer-term records and larger patient numbers may be necessary to expound the influence of BRAF and KRAS mutations on the outcomes of CRC.

APA, Harvard, Vancouver, ISO, and other styles

3

Stenson, P. D., E. Ball, K. Howells, A. Phillips, M. Mort, and D. N. Cooper. "Human Gene Mutation Database: towards a comprehensive central mutation database." Journal of Medical Genetics 45, no. 2 (September 24, 2007): 124–26. http://dx.doi.org/10.1136/jmg.2007.055210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ping, Jie, Olufunmilola Oyebamiji, Hui Yu, Scott Ness, Jeremy Chien, Fei Ye, Huining Kang, et al. "MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data." Briefings in Bioinformatics 21, no. 4 (October 7, 2019): 1479–86. http://dx.doi.org/10.1093/bib/bbz084.

Full text

Abstract:

Abstract Somatic mutation and gene expression dysregulation are considered two major tumorigenesis factors. While independent investigations of either factor pervade, studies of associations between somatic mutations and gene expression changes have been sporadic and nonsystematic. Utilizing genomic data collected from 11 315 subjects of 33 distinct cancer types, we constructed MutEx, a pan-cancer integrative genomic database. This database records the relationships among gene expression, somatic mutation and survival data for cancer patients. MutEx can be used to swiftly explore the relationship between these genomic/clinic features within and across cancer types and, more importantly, search for corroborating evidence for hypothesis inception. Our database also incorporated Gene Ontology and several pathway databases to enhance functional annotation, and elastic net and a gene expression composite score to aid in survival analysis. To demonstrate the usability of MutEx, we provide several application examples, including top somatic mutations associated with the most extensive expression dysregulation in breast cancer, differential mutational burden downstream of DNA mismatch repair gene mutations and composite gene expression score-based survival difference in breast cancer. MutEx can be accessed at http://www.innovebioinfo.com/Databases/Mutationdb_About.php.

APA, Harvard, Vancouver, ISO, and other styles

5

Nebel, Istvan T., Barbara Trültsch, and Ralf Paschke. "TSH Receptor Mutation Database." Journal of Clinical Endocrinology & Metabolism 84, no. 6 (June 1999): 2263. http://dx.doi.org/10.1210/jcem.84.6.5809-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Cooper, D. N., and Michael Krawczak. "Human Gene Mutation Database." Human Genetics 98, no. 5 (September 26, 1996): 629. http://dx.doi.org/10.1007/s004390050272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Niesler, Beate, Christine Fischer, and Gudrun A. Rappold. "The humanSHOX mutation database." Human Mutation 20, no. 5 (October 25, 2002): 338–41. http://dx.doi.org/10.1002/humu.10125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Beysen, Diane, Jo Vandesompele, Ludwine Messiaen, Anne De Paepe, and Elfride De Baere. "The humanFOXL2 mutation database." Human Mutation 24, no. 3 (2004): 189–93. http://dx.doi.org/10.1002/humu.20079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wertheim-Tysarowska, Katarzyna, Agnieszka Sobczyńska-Tomaszewska, Cezary Kowalewski, Michał Skroński, Grzegorz Święćkowski, Anna Kutkowska-Kaźmierczak, Katarzyna Woźniak, and Jerzy Bal. "The COL7A1 mutation database." Human Mutation 33, no. 2 (December 20, 2011): 327–31. http://dx.doi.org/10.1002/humu.21651.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Shemansky, Jennifer M., Lea Patrice McDaniel, Christopher Klimas, Stephen D. Dertinger, Vasily N. Dobrovolsky, Takafumi Kimoto, Katsuyoshi Horibata, James E. Polli, and Robert H. Heflich. "Pig‐agene mutation database." Environmental and Molecular Mutagenesis 60, no. 8 (June 7, 2019): 759–62. http://dx.doi.org/10.1002/em.22298.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Nowacki, P. "PAH Mutation Analysis Consortium Database: 1997. Prototype for relational locus-specific mutation databases." Nucleic Acids Research 26, no. 1 (January 1, 1998): 220–25. http://dx.doi.org/10.1093/nar/26.1.220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Bhattacharya, Sanjoy K. "Article Commentary: Prospects for Proteomics Directed Genomic and Genetic Analyses in Disease Discoveries." Proteomics Insights 2 (January 2009): PRI.S3023. http://dx.doi.org/10.4137/pri.s3023.

Full text

Abstract:

Proteomic discoveries are usually made using database searches for identification of proteins in a given protein sample derived from cells or tissues. High throughput searches leave a number of peptides not analyzed for a variety of reasons, such as posttranslational modification or a mutation that results changes in the peptide that is not present in databases. Such mutations may be critically important in causing disease conditions. Accounts from ocular diseases are presented where the search provided results often from non-conventional databases (such as structural database instead of protein database) due to the presence of information about a mutant peptide. We contemplate that better algorithms and the ability to determine probabilities of different amino acids in the available sequence may permit combinatorial analysis with genomics which may help identify new disease associated mutations directly from the sequence of the captured peptides. In addition, the de novo analysis of spectra of the unidentified peptides may provide mutation or polymorphism information enabling additional insight about the disease association of a mutation or posttranslational modification.

APA, Harvard, Vancouver, ISO, and other styles

13

Minoshima, S. "Keio Mutation Database (KMDB) for human disease gene mutations." Nucleic Acids Research 28, no. 1 (January 1, 2000): 364–68. http://dx.doi.org/10.1093/nar/28.1.364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ratbi, Ilham, Alae-eddine Gati, and Abdelaziz Sefiani. "The moroccan human mutation database." Indian Journal of Human Genetics 14, no. 3 (2008): 106. http://dx.doi.org/10.4103/0971-6866.45004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

van Durme, J. J. J. "NRMD: Nuclear Receptor Mutation Database." Nucleic Acids Research 31, no. 1 (January 1, 2003): 331–33. http://dx.doi.org/10.1093/nar/gkg122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Cotton, R. G. H., and O. Horaitis. "The HUGO Mutation Database Initiative." Pharmacogenomics Journal 2, no. 1 (January 2002): 16–19. http://dx.doi.org/10.1038/sj.tpj.6500070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sandgren, Andreas, Michael Strong, Preetika Muthukrishnan, Brian K. Weiner, George M. Church, and Megan B. Murray. "Tuberculosis Drug Resistance Mutation Database." PLoS Medicine 6, no. 2 (February 10, 2009): e1000002. http://dx.doi.org/10.1371/journal.pmed.1000002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cotton, R. G. H. "The HUGO Mutation Database Initiative." Science 279, no. 5347 (January 2, 1998): 10c—15. http://dx.doi.org/10.1126/science.279.5347.10c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lewis, P. D. "The Mammalian Gene Mutation Database." Mutagenesis 15, no. 5 (September 1, 2000): 411–14. http://dx.doi.org/10.1093/mutage/15.5.411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Krawczak, M. "The human gene mutation database." Trends in Genetics 13, no. 3 (March 1997): 121–22. http://dx.doi.org/10.1016/s0168-9525(97)01068-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

TRÜLZSCH, BARBARA, TIBOR NEBEL, and RALF PASCHKE. "The Thyrotropin Receptor Mutation Database." Thyroid 9, no. 6 (June 1999): 521–22. http://dx.doi.org/10.1089/thy.1999.9.521.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Brown, A. "The Human PAX6 Mutation Database." Nucleic Acids Research 26, no. 1 (January 1, 1998): 259–64. http://dx.doi.org/10.1093/nar/26.1.259.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Cooper, D. "The human gene mutation database." Nucleic Acids Research 26, no. 1 (January 1, 1998): 285–87. http://dx.doi.org/10.1093/nar/26.1.285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Astolfi, Annalisa, Margherita Nannini, Valentina Indio, Angela Schipani, Alessandro Rizzo, Anna Myriam Perrone, Pierandrea De Iaco, et al. "Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile." Cancers 12, no. 8 (July 31, 2020): 2126. http://dx.doi.org/10.3390/cancers12082126.

Full text

Abstract:

Uterine Leiomyosarcoma (uLMS) is by far the most common type of uterine sarcoma, characterized by an aggressive clinical course, a heterogeneous genetic profile and a very scarce response to cytotoxic chemotherapy. The genetic make-up of uLMS is an area of active study that could provide essential cues for the development of new therapeutic approaches. A total of 216 patients with uLMS from cBioPortal and AACR-GENIE databases were included in the study. The vast majority of patients (81%) carried at least one mutation in either TP53, RB1, ATRX or PTEN. The most frequently mutated gene was TP53, with 61% of the patients harboring at least one mutation, followed by RB1 at 48%. PTEN alteration was more frequent in metastases than in primary lesions, consistent with a later acquisition during tumor progression. There was a significant trend for TP53 and RB1 mutations to occur together, while both TP53 and RB1 were mutually exclusive with respect to CDKN2A/B inactivation. Overall survival did not show significant correlation with the mutational status, even if RB1 mutation emerged as a favorable prognostic factor in the TP53-mutant subgroup. This comprehensive analysis shows that uLMS is driven almost exclusively by the inactivation of tumor suppressor genes and suggests that future therapeutic strategies should be directed at targeting the main genetic drivers of uLMS oncogenesis.

APA, Harvard, Vancouver, ISO, and other styles

25

Ergoren, Mahmut Cerkez, Rameez Hassan Pirzada, Mustafa Arici, and Nedime Serakinci. "Near East University Genetic Mutation Database (NEU-GD): The first mutation database of Northern Cyprus." Gene 571, no. 1 (October 2015): 145–48. http://dx.doi.org/10.1016/j.gene.2015.07.035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Lane, D. A., T. Bayston, R. J. Olds, A. C. Fitches, D. N. Cooper, D. S. Millar, K. Jochmans, et al. "Antithrombin Mutation Database: 2nd (1997) Update." Thrombosis and Haemostasis 77, no. 01 (1997): 197–211. http://dx.doi.org/10.1055/s-0038-1655930.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lane, D. A., R. J. Olds, M. Boisclair, V. Chowdhury, S. L. Thein, D. N. Cooper, M. Blajchman, D. Perry, J. Emmerich, and M. Aiach. "Antithrombin III Mutation Database: First Update." Thrombosis and Haemostasis 70, no. 02 (1993): 361–69. http://dx.doi.org/10.1055/s-0038-1649581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Beroud, C. "p53 gene mutation: software and database." Nucleic Acids Research 24, no. 1 (January 1, 1996): 147–50. http://dx.doi.org/10.1093/nar/24.1.147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Beroud, C. "p53 gene mutation: software and database." Nucleic Acids Research 26, no. 1 (January 1, 1998): 200–204. http://dx.doi.org/10.1093/nar/26.1.200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Dalgleish, R. "The Human Collagen Mutation Database 1998." Nucleic Acids Research 26, no. 1 (January 1, 1998): 253–55. http://dx.doi.org/10.1093/nar/26.1.253.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Pan, C., J. Kim, L. Chen, Q. Wang, and C. Lee. "The HIV positive selection mutation database." Nucleic Acids Research 35, Database (January 3, 2007): D371—D375. http://dx.doi.org/10.1093/nar/gkl855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Uitto, Jouni. "Epidermolysis Bullosa: The Expanding Mutation Database." Journal of Investigative Dermatology 123, no. 4 (October 2004): xii—xiii. http://dx.doi.org/10.1111/j.0022-202x.2004.23333.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Stephenson, Alexandra, Lorraine Lau, Markus Eszlinger, and Ralf Paschke. "The Thyrotropin Receptor Mutation Database Update." Thyroid 30, no. 6 (June 1, 2020): 931–35. http://dx.doi.org/10.1089/thy.2019.0807.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Heinritz, Wolfram, Lin Shou, Andre Moschik, and Ursula G. Froster. "The human TBX5 gene mutation database." Human Mutation 26, no. 4 (2005): 397. http://dx.doi.org/10.1002/humu.9375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Hernandez, Diana, Sarah Addou, David Lee, Christine Orengo, Elizabeth A. Shephard, and Ian R. Phillips. "Trimethylaminuria and a humanFMO3 mutation database." Human Mutation 22, no. 3 (August 18, 2003): 209–13. http://dx.doi.org/10.1002/humu.10252.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Béroud, Christophe, Dalil Hamroun, Gwenaëlle Collod-Béroud, Catherine Boileau, Thierry Soussi, and Mireille Claustres. "UMD (Universal Mutation Database): 2005 update." Human Mutation 26, no. 3 (September 2005): 184–91. http://dx.doi.org/10.1002/humu.20210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ruangrit, Uttapong, Metawee Srikummool, Anunchai Assawamakin, Chumpol Ngamphiw, Suparat Chuechote, Vilasinee Thaiprasarnsup, Gallissara Agavatpanitch, et al. "Thailand mutation and variation database (ThaiMUT)." Human Mutation 29, no. 8 (August 2008): E68—E75. http://dx.doi.org/10.1002/humu.20787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Auerbach, Arleen D., and Richard G. H. Cotton. "Mutation Database Meeting, 27th March 1998." Human Mutation 12, no. 6 (1998): 367–69. http://dx.doi.org/10.1002/(sici)1098-1004(1998)12:6<367::aid-humu1>3.0.co;2-r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Zhou, Chixiang, and Phyllis Frankl. "JDAMA: Java database application mutation analyser." Software Testing, Verification and Reliability 21, no. 3 (April 28, 2011): 241–63. http://dx.doi.org/10.1002/stvr.462.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wei, Ming-Hui, Patrick W. Blake, Julia Shevchenko, and Jorge R. Toro. "The folliculin mutation database: An online database of mutations associated with Birt-Hogg-DubÃ© syndrome." Human Mutation 30, no. 9 (September 2009): E880—E890. http://dx.doi.org/10.1002/humu.21075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Pecho-Silva, Samuel, and Ana C. Navarro-Solsol. "The c.3274T> C mutation in the CFTR gene results in bronchiectasis and loss of lung function in a 44-year-old Peruvian woman: A very rare condition." Revista Peruana de Investigación en Salud 5, no. 2 (April 9, 2021): 132–35. http://dx.doi.org/10.35839/repis.5.2.1008.

Full text

Abstract:

CF is an autosomal recessive disease, requiring mutations to be present in both alleles in the CF transmembrane conductance regulatory gene (CFTR). The c.3274T> C (p.Tyr1092His) mutation is not registered in the “CFTR2 project” database, but it is registered in The Human Gene Mutation Database. Neither are the two DNAAF4 c.1177C> T (p.Leu393Phe) and DNAAF5 c.1195G> A (p.Glu399Lys) mutations found in the "CFTR Project”, and their clinical consequences are currently uncertain. Here, we report the case of a Peruvian woman presenting this mutation, bronchiectasis and loss of lung function and provide a review of the literature.

APA, Harvard, Vancouver, ISO, and other styles

42

Paalman, Mark H. "Ourania Horaitis: LinkingHuman Mutation and the HUGO-Mutation Database Initiative." Human Mutation 17, no. 1 (2000): 1–2. http://dx.doi.org/10.1002/1098-1004(2001)17:1<1::aid-humu1>3.0.co;2-#.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

ZHAO, XIN, ZUOFENG LI, and XIAOYAN ZHANG. "G6PD-MutDB: A MUTATION AND PHENOTYPE DATABASE OF GLUCOSE-6-PHOSPHATE (G6PD) DEFICIENCY." Journal of Bioinformatics and Computational Biology 08, supp01 (December 2010): 101–9. http://dx.doi.org/10.1142/s021972001000518x.

Full text

Abstract:

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common hereditary enzymatic disorder of red blood cells in humans due to mutations in the G6PD gene. The G6PD enzyme catalyzes the first step in the pentose phosphate pathway to protect cells against oxidative stress. Mutations in the G6PD gene will cause functional variants with various biochemical and clinical phenotypes. So far, about 160 mutations along with more than 400 biochemical variants have been described. G6PD-MutDB is a disease-specific resource of G6PD deficiency, collecting and integrating G6PD mutations with biochemical and clinical phenotypes. Data of G6PD deficiency is manually extracted from published papers, focusing primarily on variants with identified mutation and well-described quantitative phenotypes. G6PD-MutDB implements an approach, CNSHA predictor, to help identify a potential chronic non-spherocytic hemolytic anemia (CNSHA) phenotype of an unknown mutation. G6PD-MutDB is believed to facilitate analysis of relationship between molecular mutation and functional phenotype of G6PD deficiency owing to convenient data resource and useful tools. This database is available from .

APA, Harvard, Vancouver, ISO, and other styles

44

Wang, Yan, Fei Ran, Jin Lin, Jing Zhang, and Dan Ma. "Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL." Technology in Cancer Research & Treatment 22 (January 2023): 153303382311540. http://dx.doi.org/10.1177/15330338231154092.

Full text

Abstract:

Simultaneous mutations in Janus kinase 2 ( JAK2), calreticulin , and myeloproliferative leukemia (MPL) genes are generally not considered for characterizing Philadelphia-negative myeloproliferative neoplasms (MPNs), leading to misdiagnosis. Sanger sequencing and quantitative polymerase chain reaction were used to detect gene mutations in patients with MPN. We retrospectively screened the data of patients with double mutations in our center and from the PubMed database. Two patients tested positive for both JAK2V617F and CALR mutations (2/352 0.57%) in our center, while data of 35 patients from the PubMed database, including 26 patients with essential thrombocythemia (ET), 6 with primary myelofibrosis (PMF), 2 with unexplained thrombosis, and 1 with polycythemia vera were screened for double mutations. Among these mutations, co-mutation of JAKV617F-CALR constituted the majority (80.0%), when compared with JAKV617F-MPL (17.1%) and CALR-MPL (2.9%) mutations. Moreover, patients with concurrent mutational myeloproliferative neoplasm (MPN) were relatively older ( P = .010) with significantly higher platelet counts than their counterparts with single gene mutations ( P < .001). The occurrence of palpable splenomegaly ( P < .001) and leukocyte count ( P = .041) were also significantly different between patients with single and simultaneous gene mutations. These 4 risk factors also showed significant test effectiveness in the ET and PMF cohorts ( P < .05). In terms of clinical characteristics of patients with ET, those with JAK2V617F- CALR mutation had higher but normal hemoglobin levels ( P = .0151) than those carrying JAK2V617F- MPL mutation. From a clinical perspective, patients with multiple mutational MPN are different from those with single gene mutations. The poor treatment response by patients in our center and unfavorable indicators for patients with co-mutations in published literature indicate that customized treatment may be the best choice for patients with MPN carrying co-mutations.

APA, Harvard, Vancouver, ISO, and other styles

45

Stenson, Peter D., Edward V. Ball, Katy Howells, Andrew D. Phillips, Matthew Mort, and David N. Cooper. "The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalised genomics." Human Genomics 4, no. 2 (2009): 69. http://dx.doi.org/10.1186/1479-7364-4-2-69.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Peltomäki, Päivi, and Hans Vasen. "Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database." Disease Markers 20, no. 4-5 (2004): 269–76. http://dx.doi.org/10.1155/2004/305058.

Full text

Abstract:

In 1994, the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC) established an international database of mutations identified in families with Lynch (HNPCC) syndrome. The data are publicly available at http://www.nfdht.nl. The information stored in the database was systematically analyzed in 1997, and at that time, 126 different predisposing mutations were reported affecting the DNA mismatch repair genes MSH2 and MLH1 and occurring in 202 families. In 2003, the ICG-HNPCC and the Leeds Castle Polyposis Group (LCPG) merged into a new group, INSiGHT (International Society for Gastrointestinal Hereditary Tumors). The present update of the database of DNA mismatch repair gene mutations of INSiGHT includes 448 mutations that primarily involve MLH1 (50%), MSH2 (39%), and MSH6 (7%) and occur in 748 families from different parts of the world.

APA, Harvard, Vancouver, ISO, and other styles

47

Patrinos, George P., Sjozef van Baal, Michael B. Petersen, and Manoussos N. Papadakis. "Hellenic National Mutation Database: a prototype database for mutations leading to inherited disorders in the Hellenic population." Human Mutation 25, no. 4 (2005): 327–33. http://dx.doi.org/10.1002/humu.20157.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Barnes, Michael R. "SNP and Mutation Data on the Web – Hidden Treasures for Uncovering." Comparative and Functional Genomics 3, no. 1 (2002): 67–74. http://dx.doi.org/10.1002/cfg.131.

Full text

Abstract:

SNP data has grown exponentially over the last two years, SNP database evolution has matched this growth, as initial development of several independent SNP databases has given way to one central SNP database, dbSNP. Other SNP databases have instead evolved to complement this central database by providing gene specific focus and an increased level of curation and analysis on subsets of data, derived from the central data set. By contrast, human mutation data, which has been collected over many years, is still stored in disparate sources, although moves are afoot to move to a similar central database. These developments are timely, human mutation and polymorphism data both hold complementary keys to a better understanding of how genes function and malfunction in disease. The impending availability of a complete human genome presents us with an ideal framework to integrate both these forms of data, as our understanding of the mechanisms of disease increase, the full genomic context of variation may become increasingly significant.

APA, Harvard, Vancouver, ISO, and other styles

49

Hart, Lowell L., Kai Treuner, Li Ma, Jenna Wong, Catherine A. Schnabel, and James Andrew Reeves. "Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for PARP inhibitors." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e15080-e15080. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15080.

Full text

Abstract:

e15080 Background: Olaparib, rucaparib, and niraparib are 3 poly-ADP-ribose polymerase inhibitors (PARPi) approved by the FDA for ovarian, breast, pancreatic, prostate, fallopian tube and peritoneal cancers with BRCA mutations. Several ongoing clinical trials aim to determine the efficacy of PARPi in various other cancer types, including specific cancer subtypes, such as clear cell renal cell carcinoma and cholangiocarcinoma either as monotherapy or combination therapy; however, eligibility for PARPi therapy requires the identification of the primary tumor type and confirmation of BRCA mutation. The 92-gene assay (CancerTYPE ID) is a validated gene expression classifier of 50 tumor types and subtypes for metastatic patients with unknown or uncertain diagnoses. Multimodal biomarker testing, including next-generation sequencing (NGS), enables identification of actionable biomarkers to guide targeted therapy selection. In the current study, a database of metastatic cases that integrates tumor type with biomarker analysis was characterized to identify those eligible for PARPi treatment. Methods: MOSAIC (Molecular Synergy to Advance Individualized Cancer Care) is an IRB-approved, de-identified database of cases submitted for CancerTYPE ID testing with tissue-guided multimodal biomarker testing by NGS, including tumor mutational burden (TMB) fluorescent in situ hybridization (FISH), and microsatellite instability (MSI), and immunohistochemistry (IHC) (NeoTYPE profiles, Neogenomics). For the current study, metastatic cancers classified as ovarian, breast, pancreatic, or prostate were identified in the database, followed by NGS analysis to detect mutations in BRCA1 or BRCA2. Results: The current analysis included 2151 CancerTYPE ID cases, from which 71 ovarian, 47 breast, 12 pancreatic and 15 prostate cancer cases were identified. Out of 46 cases of ovarian cancer with molecular biomarker results, NGS identified 7 (15.3%) cases with BRCA1 mutation and 4 (8.7%) cases with BRCA2 mutation. Additionally, 4 (10.5%) cases with BRCA1 mutation and 1 (2.6%) case with BRCA2 mutation out of 38 cases of breast cancer with BRCA results were detected. No cases of prostate cancer or pancreatic cancer with mutations in BRCA1 or BRCA2 were detected. Conclusions: These findings in metastatic patients demonstrate the clinical utility of tumor type identification combined with molecular biomarker profiling, leading to additional options for patients with advanced disease. Specifically, analysis of the MOSAIC database identified a subset of patients with metastatic cancers eligible for PARPi therapy based on tumor type and BRCA mutation status. As new and approved PARPi are evaluated for efficacy in additional tumor types, patients can be identified that may be eligible for these targeted cancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

50

Stenson, Peter D., Matthew Mort, Edward V. Ball, Katy Howells, Andrew D. Phillips, Nick ST Thomas, and David N. Cooper. "The Human Gene Mutation Database: 2008 update." Genome Medicine 1, no. 1 (2009): 13. http://dx.doi.org/10.1186/gm13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!